drugset / Trial / NCT05552183
Study to Evaluate the Safety, Tolerability, and PK of Pacritinib
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1 study designed to assess the effect of hepatic insufficiency on the PK of pacritinib by study of 14-day BID dosing of pacritinib in subjects with moderate and severe hepatic impairment compared to healthy matched control subjects with normal liver function. Safety and tolerability of multiple day dosing of pacritinib in the subject populations will also be evaluated.
Timeline
- Start
- 2022-12-12
- Primary completion
- 2024-06-10
- Completion
- 2024-06-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pacritinib | Small molecule | 200 mg | Oral |
Indications
No indication recorded.